Lobe Sciences plans to advance to Phase 1 PTSD study in second half of 2022 with psilocybin and NAC
Lobe Sciences CEO Phillip Young joined Proactive to discuss the biotechnology's intention to develop a low-dose psilocybin combined with N-acetylcysteine...